Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request

PD-L1 expression in tumour-infiltrating lymphocytes is a poor prognostic factor for primary acral melanoma patients.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read Online Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: Blackwell Scientific Publications Country of Publication: England NLM ID: 7704136 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1365-2559 (Electronic) Linking ISSN: 03090167 NLM ISO Abbreviation: Histopathology Subsets: MEDLINE
    • Publication Information:
      Original Publication: Oxford, Blackwell Scientific Publications.
    • Subject Terms:
      B7-H1 Antigen/*biosynthesis ; Biomarkers, Tumor/*immunology ; Lymphocytes, Tumor-Infiltrating/*pathology ; Melanoma/*pathology ; Skin Neoplasms/*pathology; Adult ; Aged ; B7-H1 Antigen/analysis ; Disease-Free Survival ; Female ; Humans ; Kaplan-Meier Estimate ; Male ; Melanoma/mortality ; Middle Aged ; Prognosis ; Skin Neoplasms/mortality
    • Abstract:
      Aims: Programmed cell death protein 1-programmed death-ligand 1 (PD-L1) blockade immunotherapy has shown notable therapeutic benefit in metastatic melanoma, but the clinical relevance of PD-L1 expression remains unclear in melanoma, especially in acral melanoma, which is the most common subtype in Asians. The aim of this study was to evaluate the clinical effect of PD-L1 expression in primary acral melanoma.
      Methods and Results: We used immunohistochemistry to evaluate PD-L1 expression in tumour cells and tumour-infiltrating lymphocytes (TILs), and analysed its associations with clinicopathological features and survival in 78 primary acral melanoma patients. We found that expression of PD-L1 in tumour cells and TILs occurred exclusively in a tumour-stroma interface pattern, consistent with the predominant pattern of TIL distribution. The presence of peritumoral TILs was also associated with high PD-L1 expression in tumour cells. Furthermore, PD-L1 expression in tumour cells and that in TILs showed a close relationship (Spearman's rho = 0.381, P = 0.001). However, neither PD-L1 expression in tumour cells nor that in TILs was significantly correlated with clinicopathological features. In univariate analysis, cases with PD-L1-positive TILs had significantly poorer survival than those with PD-L1-negative TILs (median disease-specific survival of 40.7 months versus 78.0 months; P = 0.008). In multivariate analysis, PD-L1 expression in TILs was an independent factor for poor prognosis (P = 0.032), whereas PD-L1 expression in tumour cells was not significantly correlated with survival in univariate analysis (P = 0.378) and multivariate analysis (P = 0.354).
      Conclusion: This is the first study to demonstrate that PD-L1 expression in TILs, but not that in tumour cells, is an independent predictor of poor prognosis in acral melanoma.
      (© 2018 John Wiley & Sons Ltd.)
    • Contributed Indexing:
      Keywords: PD-L1; acral melanoma; immunohistochemistry; prognostic factor; tumour-infiltrating lymphocytes
    • Accession Number:
      0 (B7-H1 Antigen)
      0 (Biomarkers, Tumor)
      0 (CD274 protein, human)
    • Publication Date:
      Date Created: 20180412 Date Completed: 20181211 Latest Revision: 20210103
    • Publication Date:
      20240513
    • Accession Number:
      10.1111/his.13527
    • Accession Number:
      29637587